Clinical data | |
---|---|
Other names | Acetylhexa-L-lysyl-α-MSH |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C113H181N33O25S |
Molar mass | 2433.96 g·mol−1 |
3D model (JSmol) | |
| |
|
Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury.[1][2] It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors.[3] Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models,[4][5] and development was not further pursued.[1][2]
| |
---|---|
MC1 |
|
MC2 |
|
MC3 |
|
MC4 |
|
MC5 |
|
Unsorted |
|
Others |
|
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |